Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Revisiting the role of ABC transporters in multidrug-resistant cancer
Most patients who die of cancer have disseminated disease that has become resistant to
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP …
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Targeting ALK: precision medicine takes on drug resistance
JJ Lin, GJ Riely, AT Shaw - Cancer discovery, 2017 - AACR
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
R Dziadziuszko, MG Krebs, F De Braud… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1
(ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results …
(ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results …
Targeting TRK family proteins in cancer
YB Khotskaya, VR Holla, AF Farago, KRM Shaw… - Pharmacology & …, 2017 - Elsevier
The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins,
which are encoded by NTRK1, NTRK2 and NTRK3 genes, respectively. Binding of …
which are encoded by NTRK1, NTRK2 and NTRK3 genes, respectively. Binding of …
Current approaches to the treatment of metastatic brain tumours
Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency
and are an important complication in the overall management of many cancers. Importantly …
and are an important complication in the overall management of many cancers. Importantly …
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
R Katayama, CM Lovly, AT Shaw - Clinical Cancer Research, 2015 - AACR
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as
a component of the fusion protein nucleophosmin (NPM)–ALK in anaplastic large-cell …
a component of the fusion protein nucleophosmin (NPM)–ALK in anaplastic large-cell …
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Brain metastases (BM) occur frequently in many cancers, particularly non–small cell lung
cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with …
cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with …
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
The incidence of brain metastases has increased as a result of improved systemic control
and advances in imaging. However, development of novel therapeutics with CNS activity …
and advances in imaging. However, development of novel therapeutics with CNS activity …